Help guide our efforts to modernize
Send us your comments by March 14, 2020. Menu

CYP2C19 Genetic Polymorphism on the Accuracy of Proton-Pump Inhibitor Testing

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00354757
Recruitment Status : Completed
First Posted : July 20, 2006
Last Update Posted : December 3, 2012
Information provided by (Responsible Party):
National Taiwan University Hospital

Brief Summary:

Background/Aim: To evaluate the optimal dosage of rabeprazole for proton-pump inhibitor (PPI) testing of gastroesophageal reflux disease (GERD) and to test the influence of cytochrome P (CYP) 2C19 polymorphism in a population with a high prevalence of people who poorly metabolize PPIs.

Patients and Methods: In this randomized, open-label trial, patients with symptoms suggestive of GERD were randomized to receive a two-week test with 20-mg or 40-mg rabeprazole after diagnostic endoscopy. Symptom response was assessed with a four-grade daily record; in addition, DNA from peripheral blood leukocytes was genotyped for CYP2C19 polymorphism with polymerase chain reaction-restrict fragment length polymorphism (PCR-RFLP) technique.

Condition or disease Intervention/treatment Phase
GERD Drug: rabeprazole Phase 4

Show Show detailed description

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 200 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Diagnostic
Official Title: The Influence of CYP2C19 Genetic Polymorphism and Dosage of Rabeprazole on the Accuracy of Proton-Pump Inhibitor Testing in Chinese Patients With Gastroesophageal Reflux Disease
Study Start Date : June 2005
Actual Primary Completion Date : June 2008
Actual Study Completion Date : December 2008

Resource links provided by the National Library of Medicine

MedlinePlus related topics: GERD

Arm Intervention/treatment
Active Comparator: 2 arms
Drug: rabeprazole
Active Comparator: PPI
Drug: rabeprazole

Primary Outcome Measures :
  1. Symptom response with a four-grade daily record. [ Time Frame: 2 weeks ]
    GERD symptom assessment

Secondary Outcome Measures :
  1. CYP2C19 polymorphism [ Time Frame: 2 weeks ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   20 Years to 80 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • A consecutive series of patients with symptoms suggestive of GERD were enrolled from the Gastroenterology outpatient clinic in our institution. The typical GERD symptom was defined as heartburn and/or acid regurgitation of at least three episodes per week for a minimum of three months.

Exclusion Criteria:

  • Patients who received concurrent PPI treatment, had a medical contraindication to rabeprazole therapy, reported a history of peptic ulcer disease or gastrointestinal surgery, peptic ulcer disease or malignancy proven by endoscopy, the presence of alarm features (e.g., dysphagia, weight loss, bleeding, abdominal mass, and/or anemia), or who were unwilling or unable to provide informed consent were excluded from the study.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00354757

Layout table for location information
National Taiwan Univeristy Hospital
Taipei, Taiwan, 100
Sponsors and Collaborators
National Taiwan University Hospital
Layout table for investigator information
Study Director: Ming-Shiang Wu, PHD National Taiwan University Hospital

Publications of Results:
Abstract, DDW, 2006, Los Angeles

Layout table for additonal information
Responsible Party: National Taiwan University Hospital Identifier: NCT00354757    
Other Study ID Numbers: 940711
First Posted: July 20, 2006    Key Record Dates
Last Update Posted: December 3, 2012
Last Verified: November 2012
Keywords provided by National Taiwan University Hospital:
gastroesophageal reflux disease, proton-pump inhibitor test
Additional relevant MeSH terms:
Layout table for MeSH terms
Gastroesophageal Reflux
Esophageal Motility Disorders
Deglutition Disorders
Esophageal Diseases
Gastrointestinal Diseases
Digestive System Diseases
Proton Pump Inhibitors
Anti-Ulcer Agents
Gastrointestinal Agents
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action